No CrossRef data available.
Published online by Cambridge University Press: 27 August 2024
There has been growing evidence to support the hypothesis that inflammation is involved in the pathogenesis of schizophrenia.
The aim of the present literature review was to assess the efficacy of acetylsalicylic acid (ASA) as an adjuvant agent in the treatment of an acute exacerbation of schizophrenia.
We searched randomized clinical trials based on regular searches of MEDLINE, Embase, PubMed.
We included four studies. The results were in favor of the efficacy of ASA in the study where authors targeted early psychosis. Illness duration seems to predict response to anti-inflammatory agents.
Further studies of early stages of schizophrenia are helpful.
None Declared
Comments
No Comments have been published for this article.